General Information of Drug Combination (ID: DC6KQ78)

Drug Combination Name
Amonafide Arfolitixorin
Indication
Disease Entry Status REF
Colon adenocarcinoma Investigative [1]
Component Drugs Amonafide   DMAH59S Arfolitixorin   DMIXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: COLO 205
Zero Interaction Potency (ZIP) Score: 1.89
Bliss Independence Score: 1.62
Loewe Additivity Score: 5.71
LHighest Single Agent (HSA) Score: 7.84

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DC42ODQ HL-60(TB) Investigative [4]
Anaplastic large cell lymphoma DCW9VC2 SR Investigative [4]
Glioma DCBQIM9 SF-268 Investigative [4]
Large cell lung carcinoma DCH6E61 NCI-H460 Investigative [4]
Malignant melanoma DCE28IS LOX IMVI Investigative [4]
Carcinoma DCGUCD8 RXF 393 Investigative [1]
Colon carcinoma DCZLLFO KM12 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.